{"filing":{"accession_number":"0001493152-26-035861","cik":"0001725430","ticker":"INBS","company_name":"INTELLIGENT BIO SOLUTIONS INC.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"form8-k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1725430/000149315226035861/form8-k.htm"},"events":[{"id":23257,"run_id":21027,"accession_number":"0001493152-26-035861","anchor_item_number":"7.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"The disclosure announces completion of an Interference Study for the Intelligent Fingerprinting Drug Screening System, a key regulatory milestone supporting the Company's FDA 510(k) submission planned for H2 2026. This is a material operational/product development event—the study validates system performance under real-world conditions and directly advances the Company's path to U.S. market entry in a multi-billion-dollar drug screening market. While not a specific named event type, it is clearly operational and strategic in nature, making operational_other the most appropriate classification.","company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23444,"accession_number":"0001493152-26-035861","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces completion of an Interference Study for the Intelligent Fingerprinting Drug Screening System, a key regulatory milestone supporting the Company's FDA 510(k) submission planned for H2 2026. This is a material operational/product development event—the study validates system performance under real-world conditions and directly advances the Company's path to U.S. market entry in a multi-billion-dollar drug screening market. While not a specific named event type, it is clearly operational and strategic in nature, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:53:46.976901+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23444,"accession_number":"0001493152-26-035861","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"The disclosure announces completion of an Interference Study for the Intelligent Fingerprinting Drug Screening System, a key regulatory milestone supporting the Company's FDA 510(k) submission planned for H2 2026. This is a material operational/product development event—the study validates system performance under real-world conditions and directly advances the Company's path to U.S. market entry in a multi-billion-dollar drug screening market. While not a specific named event type, it is clearly operational and strategic in nature, making operational_other the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T00:53:46.976901+00:00","company_name":"INTELLIGENT BIO SOLUTIONS INC.","ticker":"INBS","filing_date":"2026-08-03"}]}